2126 — JW (Cayman) Therapeutics Co Share Price
0.000.00%
Last trade - 00:00- HK$640.80m
- HK$284.21m
- CNY158.22m
- 32
- 29
- 70
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.52 | ||
| Price to Tang. Book | 1.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.93% | ||
| Return on Equity | -41.4% | ||
| Operating Margin | -383.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | 30.8 | 145.7 | 173.86 | 158.22 | 317.78 | 550.89 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 6th, 2017
- Public Since
- November 3rd, 2020
- No. of Employees
- 281
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 416,106,450
- Address
- No 225 Meisheng Road, SHANGHAI, KY1-1104
- Web
- https://www.jwtherapeutics.com/
- Phone
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 2126
Half Year 2025 JW (Cayman) Therapeutics Co Ltd Earnings Release
Similar to 2126
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the JW (Cayman) Therapeutics Co share price?
As of Today at 21:29 UTC, shares in JW (Cayman) Therapeutics Co are trading at HK$1.57. This share price information is delayed by 15 minutes.
How has the JW (Cayman) Therapeutics Co share price performed this year?
Shares in JW (Cayman) Therapeutics Co last closed at HK$1.57 and the price had moved by -10.29% over the past 365 days. In terms of relative price strength the JW (Cayman) Therapeutics Co share price has underperformed the FTSE Developed Asia Pacific Index by -9.26% over the past year.
What are the analyst and broker recommendations for JW (Cayman) Therapeutics Co?
The overall consensus recommendation for JW (Cayman) Therapeutics Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the JW (Cayman) Therapeutics Co dividend yield?
JW (Cayman) Therapeutics Co does not currently pay a dividend.
Does JW (Cayman) Therapeutics Co pay a dividend?
JW (Cayman) Therapeutics Co does not currently pay a dividend.
When does JW (Cayman) Therapeutics Co next pay dividends?
JW (Cayman) Therapeutics Co does not currently pay a dividend.
How do I buy JW (Cayman) Therapeutics Co shares?
To buy shares in JW (Cayman) Therapeutics Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of JW (Cayman) Therapeutics Co?
As of the previous close price of HK$1.57, shares in JW (Cayman) Therapeutics Co had a market capitalisation of HK$640.80m.
Where are JW (Cayman) Therapeutics Co shares listed?
Here are the trading details for JW (Cayman) Therapeutics Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2126
What kind of share is JW (Cayman) Therapeutics Co?
Based on an overall assessment of its quality, value and momentum JW (Cayman) Therapeutics Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a JW (Cayman) Therapeutics Co share price forecast for 2025?
The analyst consensus target price for shares in JW (Cayman) Therapeutics Co is HK$2.44. That is 55.27% above the last closing price of HK$1.57.
Analysts covering JW (Cayman) Therapeutics Co currently have a consensus Earnings Per Share (EPS) forecast of -CNY1.46 for the next financial year.
Find out moreWhat is the trend in the JW (Cayman) Therapeutics Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like JW (Cayman) Therapeutics Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +0.83%.
As of the last closing price of HK$1.57, shares in JW (Cayman) Therapeutics Co were trading -0.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the JW (Cayman) Therapeutics Co PE Ratio?
The JW (Cayman) Therapeutics Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of JW (Cayman) Therapeutics Co?
We do not have data on JW (Cayman) Therapeutics Co's directors